DrugPatentWatch Database Preview
BEPREVE Drug Profile
When do Bepreve patents expire, and what generic alternatives are available?
Bepreve is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.
This drug has forty-five patent family members in sixteen countries.
The generic ingredient in BEPREVE is bepotastine besilate. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the bepotastine besilate profile page.
Summary for BEPREVE
| International Patents: | 45 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 60 |
| Clinical Trials: | 5 |
| Patent Applications: | 15 |
| Drug Prices: | Drug price information for BEPREVE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for BEPREVE |
| DailyMed Link: | BEPREVE at DailyMed |
Generic Entry Opportunity Date for BEPREVE
Generic Entry Date for BEPREVE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION/DROPS;OPHTHALMIC |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for BEPREVE
| Drug Class | Histamine-1 Receptor Antagonist |
Synonyms for BEPREVE
| (+)-(S)-4-(4-((4-Chlorophenyl)(2-pyridyl)methoxy)piperidino)butyric acid monobenzenesulfonate |
| (+)-(S)-4-[4-[1-(4-Chlorophenyl)-1-(2-pyridyl)methoxy]piperidin-1-yl]butyric acid benzenesulfonate |
| (S)-4-(4-((4-chlorophenyl)(pyridin-2-yl)methoxy)piperidin-1-yl)butanoic acid compound with benzenesulfonic acid (1:1) |
| (S)-4-[4-(4-Chlorophenyl-2-pyridylmethoxy)piperidinyl]butyric Acid Benzenesulfonate |
| (s)-4-[4-[(4-chlorophenyl)(2-pyridyl)-methoxy]piperidino]butanoic acid monobenzenesulfonic acid salt |
| (s)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butanoic acid monobenzenesulfonic acid salt |
| 1-Piperidinebutanoic acid, 4-((4-chlorophenyl)-2-pyridinylmethoxy)- (S)-, monobenzenesulfonate |
| 1-piperidinebutanoic acid, 4-[(4-chlorophenyl)-2-pyridinylmethoxy]-, (s)-, monobenzenesulfonate |
| 1-piperidinebutanoic acid, 4-[(s)-(4-chlorophenyl)-2-pyridinylmethoxy]-, monobenzenesulfonate |
| 190786-44-8 |
| 4-((4-Chlorophenyl)-2-pyridinylmethoxy)- (S)-1-piperidinebutanoic acid monobenzenesulfonate |
| 4-[(S)-(4-Chlorophenyl)-2-pyridinylmethoxy]-1-piperidinebutanoic Acid Benzenesulfonate |
| 4-[4-[(r)-(4-chlorophenyl)-pyridin-2-yl-methoxy]-1-piperidyl]butanoic acid |
| 4-{4-[(s)-(4-chlorophenyl)(pyridin-2-yl)methoxy]piperidin-1-yl}butanoic acid benzenesulfonate |
| 6W18MO1QR3 |
| 786B448 |
| ABP001064 |
| AC-24015 |
| AC1L4UXJ |
| AC1Q6WSY |
| AK322015 |
| AKOS025401655 |
| AN-5247 |
| API0001668 |
| AS-17863 |
| BC214879 |
| benzenesulfonic acid; 4-[4-[(S)-(4-chlorophenyl)-(2-pyridyl)methoxy]-1-piperidyl]butanoic acid |
| benzenesulfonic acid; 4-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid |
| benzenesulfonic acid;4-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid |
| Bepomax |
| Bepotastine (Beslilate) |
| Bepotastine benzenesulfonate |
| Bepotastine Benzenesulfonate Salt |
| Bepotastine besilate |
| Bepotastine besilate (JP17) |
| Bepotastine Besitate |
| Bepotastine Beslilat |
| Bepotastine besylate |
| Bepotastine besylate (USAN) |
| Bepotastine besylate [USAN] |
| Bepreve (TN) |
| Betotastine besilate |
| C27H31ClN2O6S |
| CB0259 |
| CHEBI:31281 |
| CHEMBL1201759 |
| CS-0383 |
| CTK4E0497 |
| D01654 |
| DTXSID80172577 |
| FT-0655883 |
| HY-A0015 |
| J-012325 |
| KS-00000FR0 |
| LS-114358 |
| MFCD01938491 |
| MolPort-005-938-034 |
| PubChem19122 |
| s3037 |
| SC-47417 |
| SCHEMBL1287638 |
| Talion |
| Talion (TN) |
| TAU-284 |
| tau284 |
| UDGHXQPQKQPSBB-BOXHHOBZSA-N |
| UNII-6W18MO1QR3 |
| V2224 |
| W-5279 |
US Patents and Regulatory Information for BEPREVE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | BEPREVE | bepotastine besilate | SOLUTION/DROPS;OPHTHALMIC | 022288-001 | Sep 8, 2009 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Bausch And Lomb Inc | BEPREVE | bepotastine besilate | SOLUTION/DROPS;OPHTHALMIC | 022288-001 | Sep 8, 2009 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Bausch And Lomb Inc | BEPREVE | bepotastine besilate | SOLUTION/DROPS;OPHTHALMIC | 022288-001 | Sep 8, 2009 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for BEPREVE
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Ophthalmic Solution | 1.5% | ➤ Subscribe | ➤ Try a Free Trial |
International Patents for BEPREVE
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Spain | 2173499 | ➤ Try a Free Trial |
| Japan | 2014012732 | ➤ Try a Free Trial |
| Denmark | 0949260 | ➤ Try a Free Trial |
| South Korea | 20050025137 | ➤ Try a Free Trial |
| Japan | 2016006059 | ➤ Try a Free Trial |
| European Patent Office | 1525884 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
